Scroll To Top
Search by Speciality

EuroGin International Multidisciplinary Congress

Salzburg Congress Center * | Salzburg, AUSTRIA
From 400 to 840 EUR
Event Preview
EXPIRED
This event
is Finished
Title: EuroGin International Multidisciplinary Congress
Specialty: Pathology
Dates: From Jun, 15, 2016 to Jun, 18, 2016
Location: Salzburg, AUSTRIA
Type: Congress
Registration Cost: From 400 to 840 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Jun
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Salzburg, Austria.
General Info
Event Venue:

Salzburg Congress Center *

Salzburg, AUSTRIA Visit the Venue to read more
Currency:
EUR
Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

MESSAGE FROM THE HONORARY PRESIDENTS OF EUROGIN 2016 


It is with great pleasure that we welcome you at EUROGIN 2016 in Salzburg, Austria. Salzburg is one of the most beautiful cities in the heart of Europe at the border between Austria and Germany. The city is the birthplace of Wolfgang Amadeus Mozart, the location of the Oscar-winning movie “The Sound of Music” and the place of the world´s most renowned festival of classical music (Salzburger Festspiele). It is surrounded by a wonderful landscape with alpine mountains and beautiful lakes. 


The annual edition of EUROGIN is a great reminder of what basic and clinical sciences have achieved to date in the battle against cervical cancer - a leading cause of death in women worldwide. During the past two decades EUROGIN has furthermore been an excellent platform to communicate and discuss findings about the entire spectrum of human papillomavirus (HPV) related diseases. One highlight of the recent past was the FDA and EMA approval of the nona-valent HPV vaccine, which represents an important step in the final elimination of cervical cancer if vaccination coverage significantly improves globally.


A new era of cervical cancer screening had begun when the FDA approved an HPV test for primary cervical cancer screening in the US. This opened the door for an entire array of new debates including the lengths of the respective screening intervals, at what age of the woman screening should begin and end, and finally what the triage strategy should be. In 2015 the Netherlands and Australia approved primary HPV testing to be integrated in their screening programs. As a consequence an increasing number of screening tests are being developed, including cellular markers for detection of underlying disease. The common believe is that cervical cancer screening is continuously developing towards the usage of molecular markers opening the gateway for personalized medicine, which will compete with the performance of cytology-based methods. Finally, the development of novel therapeutic vaccines that are currently tested in clinical trials represents a significant step in improving cervical cancer treatment options, which hasn’t seen major advances in the past decades. 


Today, as we know that HPV is the cause of numerous diseases, this conference has become of interest for a broad variety of clinical and scientific specialists. There is a unique balance between virologists, epidemiologists, public health experts and clinicians in the field of HPV research. In order to further advance HPV related cancer prevention and treatment, it is of uttermost importance for basic and clinical sciences to continuously collaborate. The EUROGIN conference is the ideal platform for scientists of both disciplines to network, share research ideas and discuss the latest advances in this challenging and multifarious field of investigation. Hence, we wish all participants a great experience at this year’s EUROGIN congress.


Thomas Iftner


Elmar Joura


Congress Presidents

Registration Needs updating Register Now
Currency:

EUR

Registration Cost
Type
Early Registration

2016-01-31
Late Registration From: 2016-02-01 To: 0--
On site Registration
Standard fee
600
740
840
Students
400
480
560
Austria/Germany
460
540
620

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts

Accommodation
Accommodation:

Salzburg Congress Center   

7, Rainerstrase Salzburg Austria

Scientific Content Up to Date
Submission Info

Submission of an abstract implies the commitment that the presenting author registers for the EUROGIN 2016 Congress and that financial resources to attend are available;

Authors are requested to register within 10 days after having received their provisional notification of acceptance. Abstracts of authors not registered by March 20, 2016 will not be taken into consideration for the final program. For special cases like group registrations, please contact the Congress Secretariat at: admin@eurogin.com

Abstracts must be submitted and presented in ENGLISH

Abstracts should be prepared in accordance to the instructions below and submitted to admin@eurogin.com. For further information, please refer to the abstract template form. Abstracts that do not comply with the editing instructions will not be considered;

For Free Communications (oral) or Poster sessions, only ONE abstract can be submitted per person (author);

Original scientific material is welcome and preference is given to recent findings not published yet at the date of the Congress;

Abstracts will be peer reviewed and classified by experts in one of the categories (topics) listed; they will be allocated for oral or poster presentation. Authors who do not wish to be considered for oral presentation are requested to indicate this when submitting. However, please note, that the Scientific Committee will make the final decision for the mode of presentation;

The final decision of the Scientific Committee will be announced before March 10, 2016;

Authors agree that their abstract will be published in the Congress Program & Abstract book which will be provided to all registered participants of the Congress;

All accepted abstract authors will receive confirmation by email. Please do not forget to indicate your correct email address and telephone number when submitting your abstract;

Most accepted abstracts will be allocated for poster presentation. Detailed technical instructions will be made available to the authors in due time


   

Abstract Editing Instructions  


Abstracts must be submitted through the online submission system;

Maximum number of words for body of abstract: 250 words;

The title must be written in UPPER CASE (capitals) and in bold; (keep it brief, clearly indicating the nature of the investigation. It should not exceed 2 lines) ;

Please avoid complex mathematical formulae ;

Abstracts should be structured in three sections, clearly mentioned as such: Objectives – Methods – Results – Conclusions;

Authors should be listed by initial of the first name only (do not include full first names) and last name (family name). ONE author must be identified as the PRESENTING author by underlining his name;

Give professional address of all authors: Name of hospital, unit or laboratory, city and country in lower case. No other indications are to be given. If different affiliations, please use number notations;

Do not indent spaces on the first line of each paragraph. No space should be given between paragraphs. Use international standards for scientific articles ;

Only standard abbreviations may be used without definition. Data must be given in units widely used in literature;

Only essential references should be included and put in brackets at the end of the abstract: Numbers in the text may refer to them;

Drugs must be identified by their generic names


  

Abstract Topics   


For review purposes, abstracts are classified according to the following list. Select only 1 topic on our submission form:


 

Viral and molecular biology

Epidemiology and natural history

Pathogenesis

Immunology

HPV prophylactic vaccines: clinical aspects

HPV prophylactic vaccines: basic science

HPV therapeutic vaccines

HPV testing

Immunotherapy, Immuno-oncology

Genotyping

Molecular markers

Screening methods

Liquid based cytology

Automation in cytology

New technologies

Diagnostic procedures

Colposcopy

Cervical neoplasia

Vaginal neoplasia

Vulvar diseases and neoplasia

Anal neoplasia

Oral HPV infection

HPV and oropharynx / Head and neck cancer

HPV and associated skin diseases

Genital warts

Sexually transmitted diseases and HIV infection

Conventional therapies

New treatments - Immunotherapy

Economics and modelling

Advocacy, acceptability and psychology

Health education

Low resource settings

Sponsors Exhibitors
General Info

EUROGIN Contact Information


EUROGIN 

174, rue de Courcelles - 75017 Paris, France


Phone : +33 1 44 40 01 20

Fax: +33 1 47 66 74 70

E-mail: admin@eurogin.com

Contact
Organising Agency

EUROGIN Contact Information


EUROGIN 

174, rue de Courcelles - 75017 Paris, France


Phone : +33 1 44 40 01 20

Fax: +33 1 47 66 74 70

E-mail: admin@eurogin.com

Official Event Webpage
Event map
Revelant Events